Portal de Periódicos da CAPES

Immunogenicity of the BA.1 and BA.4/BA.5 Severe Acute Respiratory Syndrome Coronavirus 2 Bivalent Boosts: Preliminary Results From the COVAIL Randomized Clinical Trial

2023; Oxford University Press; Volume: 77; Issue: 4 Linguagem: Inglês

10.1093/cid/ciad209

1537-6591

Angela R. Branche, Nadine Rouphael, Cecilia Losada, Lindsey R. Baden, Evan J. Anderson, Anne F. Luetkemeyer, David Diemert, Patricia Winokur, Rachel M. Presti, Angelica C Kottkamp, Ann R. Falsey, Sharon E. Frey, Richard Rupp, Martín Bäcker, Richard M. Novak, Emmanuel B. Walter, Lisa A. Jackson, Susan J. Little, Lilly Cheng Immergluck, Siham Mahgoub, Jennifer A. Whitaker, Tara M Babu, Paul Goepfert, Dahlene N. Fusco, Robert L. Atmar, Christine M. Posavad, Antonia Netzl, Derek J. Smith, Kalyani Telu, Jinjian Mu, Mat Makowski, Mamodikoe Makhene, Sonja Crandon, David C. Montefiori, Paul C. Roberts, John H. Beigel,

Animal Virus Infections Studies

Abstract In a randomized clinical trial, we compare early neutralizing antibody responses after boosting with bivalent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) messenger RNA (mRNA) vaccines based on either BA.1 or BA.4/BA.5 Omicron spike protein combined with wild-type spike. Responses against SARS-CoV-2 variants exhibited the greatest reduction in titers against currently circulating Omicron subvariants for both bivalent vaccines.